Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Ulrik Lassen(Rigshospitalet), Élena Elez(Universitat Autònoma de Barcelona), Antoîne Italiano(Institut Bergonié), Giuseppe Curigliano(University of Milan), Milind Javle(The University of Texas MD Anderson Cancer Center), Filippo de Braud(Fondazione IRCCS Istituto Nazionale dei Tumori), Gerald W. Prager(Comprehensive Cancer Center Vienna), Richard Greil(Paracelsus Medical University), Alexander Stein(University Medical Center Hamburg-Eppendorf), Angelica Fasolo(IRCCS Ospedale San Raffaele), Jan H.M. Schellens(The Netherlands Cancer Institute), Patrick Y. Wen(Dana-Farber Cancer Institute), Kert Viele(University of Kentucky), Aislyn Boran, Eduard Gasal(Center for Global Development), Paul Burgess(Novartis (Switzerland)), Palanichamy Ilankumaran(Center for Global Development), Zev A. Wainberg(University of California, Los Angeles)
Cited by 511
Abstract
Related Papers
No related papers found
Powered by citation graph analysis